---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-163990"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T04:10:58.797158+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vor Bio reports engraftment data from 5 AML patients in trem-cel study; FDA clears VCAR33 ALLO IND

## Summary
- All 5 trem-cel patients achieved neutrophil engraftment in 10-11 days; high myeloid donor chimerism at day 28.
- Patient 2 had secondary graft failure coincident with coronavirus hKU1 and antimicrobials; backup graft restored engraftment.
- Patient 3 has recovering platelets with autoimmune thrombocytopenia; count 15,000/µL independent of transfusions.
- Patients 4 and 5 had normal engraftment and recovery with no unexpected adverse events; cell doses met release criteria.
- FDA cleared IND for VCAR33 ALLO (allogeneic CAR-T targeting CD33); VBP301 trial to focus on relapsed post-allo-SCT patients.

## SEC filing metadata
- accession: 0001193125-23-163990
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312523163990/0001193125-23-163990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312523163990/d623996d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-163990
- JSON: https://secwatch.observer/filing/0001193125-23-163990.json
- Plain text: https://secwatch.observer/filing/0001193125-23-163990.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.